文献速递主动脉疾病

Seal®胸主动脉支架治疗钝性创伤性主动脉损伤的韩国多中心回顾性研究中远期结果

Clinical Outcomes of the Seal® Thoracic Stent Graft for Traumatic Aortic Injury in a Korean Multicenter Retrospective Study.
PubMed 文献 · Ann Vasc Surg · 2019-08-06

该韩国多中心回顾性研究纳入2007至2013年99例钝性创伤性主动脉损伤(TAI)患者,均使用Seal®胸主动脉支架行TEVAR。技术成功率98%,平均随访49个月,无主动脉相关死亡或开放转手术,30天全因死亡率5%,1年8%。结论认为中远期结局良好,主要不良事件发生率低。

要点

  • Seal®支架TEVAR治疗钝性TAI技术成功率98%,中远期无主动脉相关死亡。
  • 迟发左锁骨下动脉闭塞需颈锁骨下动脉旁路者8例,无迟发卒中或截瘫。
  • 30天全因死亡率5%,1年8%,5年生存率89%。

核心结论

  • Seal®胸主动脉支架行TEVAR治疗钝性TAI中远期结局良好,术后主要不良事件发生率低。

研究设计与样本

  • 韩国多中心回顾性研究,纳入2007至2013年使用Seal®胸主动脉支架行TEVAR的钝性TAI患者99例,其中男性54%,平均年龄48岁。

主要发现

  • III级及以上损伤占95%,包括15例胸主动脉自由破裂,64%损伤位于III区。
  • 技术成功率98%,院内死亡8例,30天卒中2例。
  • 平均随访49±26个月(中位48个月,范围0-117个月)内无迟发卒中或截瘫,无主动脉相关死亡或开放转手术。
  • 8例患者行二次手术,均为迟发左锁骨下动脉闭塞的颈锁骨下动脉旁路术。
  • 30天全因死亡率5%,1年8%;生存率30天95%、1年92%、3年92%、5年89%;术后18个月发生1例Ia型内漏。

临床怎么用

  • 对于钝性TAI,Seal®胸主动脉支架TEVAR可作为有效治疗选择,技术成功率高且中远期主动脉相关并发症低。
  • 术后需关注迟发左锁骨下动脉闭塞,必要时行颈锁骨下动脉旁路术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thoracic endovascular aneurysm repair (TEVAR) has been used as a primary treatment for blunt traumatic aortic injury (TAI). However, the outcomes of midterm surveillance of Seal® stent-graft durability for TAI have not been extensively studied. Thus, we aimed to report the midterm outcomes of TEVAR using the Seal® stent graft for blunt TAI. METHODS: Patients with blunt TAI treated with TEVAR using the Seal® thoracic stent graft between 2007 and 2013 in Korea were included. Midterm outcomes included technical/clinical success, in-hospital death, aorta/procedure/device-related adverse events, secondary procedures, and 30-day and all-cause mortality. RESULTS: A total of 99 patients (54% men; mean age, 48 years) were included. Grade III or higher injuries were present in 95% of patients, including 15 free ruptures of the thoracic aorta, and 64% of injuries were located in zone III. The median procedure and hospitalization duration were 90 min and 11 days, respectively. The technical success rate was 98%. The number of in-hospital mortalities (n = 8) and stroke (n = 2) were observed at 30 days. Late stroke and paraplegia (>30 days) were not observed during the mean 49 ± 26 months of follow-up (median, 48 months; range, 0-117 months). There were no aorta-related mortalities or conversions to open repair. Secondary procedures were performed in 8 patients, all of which were carotid-subclavian bypasses for delayed left subclavian occlusion. The all-cause mortality rate was 5% at 30 days and 8% at 1 year. The survival rate was 95% at 30 days, 92% at 1 year, 92% at 3 years, and 89% at 5 years. One type Ia endoleak occurred at 18 months after the procedure. CONCLUSIONS: TEVAR with the Seal® stent graft for TAI showed favorable midterm outcomes. The incidence of major adverse events after the procedure was low.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Kim HM, Cho YK, Kim JH, et al. Clinical Outcomes of the Seal® Thoracic Stent Graft for Traumatic Aortic Injury in a Korean Multicenter Retrospective Study. Ann Vasc Surg. 2019. PMID: 31394246. doi:10.1016/j.avsg.2019.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。